Repligen | RGEN - 流动负债



金融业
股票价格
USD
资产
USD 2.95B
现金及等价物
USD 606.78M
销售成本
USD 94.09M
流动资产
USD 1.2B
流动负债
USD 132.66M
债务
USD 690.94M
EBIT
USD 21.13M
EBITDA
USD 43.77M
员工
1.78K
EPS每股收益
USD 0.54
股本和储备
USD 2.11B
销售毛利
USD 110.04M
债务利息支出
USD 5.66M
利息收入
USD 7.31M
贷款资金
USD 551.05M
市值
USD 9.21B
净收入
USD 5.01M
营业费用
USD 183M
营业利润
USD 21.13M
普通股股本
USD 56.43M
PE价格收益
105.09
税前利润
USD 14.15M
销售收入
USD 204M
销售和管理费用
USD 76.62M
股票
USD 186.6M
贸易债权人
USD 33.23M
应收帐款人
USD 157.71M


流动负债 更改 日
Agilent USD 2.27B 35M 2026-03
Align Technology USD 1.91B 2.74M 2026-06
Bio Techne USD 153.28M 12.85M 2026-03
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Bruker USD 1.2B 150.4M 2026-06
Charles River Laboratories USD 1.13B 41.04M 2026-06
Danaher USD 8.1B 645M 2026-06
Dentsply International USD 1.18B 22M 2026-06
General Electric Aerospace USD 40.43B 403M 2026-06
Henry Schein USD 3.49B 191M 2026-06
Illumina USD 1.58B 12M 2026-06
IQVIA Holdings USD 8.82B 486M 2026-06
Mettler Toledo International USD 1.2B 92.14M 2026-06
Myriad Genetics USD 130.7M 500K 2026-06
OraSure Technologies USD 25.12M 18.96M 2026-06
Pacific Biosciences Of California USD 68.81M 3.45M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Repligen USD 132.66M 6.45M 2026-06
Revvity USD 1.28B 37.71M 2026-06
Standard Biotools USD 42.2M 66.1M 2026-03
Thermo Fisher Scientific USD 15.07B 448M 2026-06
Waters USD 2.27B 1.03B 2026-03
West Pharmaceutical Services USD 640.5M 33.5M 2026-06